Arcus Biosciences, Inc.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies. Its pipeline includes several investigational drugs targeting various cancers. Key products include Casdatifan, a HIF-2a inhibitor for kidney cancer; Domvanalimab, an anti-TIGIT antibody for lung and gastrointestinal cancers; Zimberelimab, an anti-PD-1 antibody; Quemliclustat, a CD73 inhibitor for lung and pancreatic cancer; AB598, a CD39 antibody for gastrointestinal cancer; and AB801, an AXL inhibitor for lung cancer. The company also has collaborations with AstraZeneca and Bristol-Myers Squibb for combination therapies in kidney cancer and non-small cell lung cancer.

Arcus Biosciences is listed on the New York Stock Exchange (NYSE) under the ticker symbol RCUS. Its shares are traded in US Dollars (USD), as the company is based in the United States and reports its financials in USD. The exchange and currency are standard for US-listed companies, providing liquidity and access to global investors.

Arcus Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for cancer, a field that requires significant scientific expertise and regulatory approvals. The company's work involves clinical trials, drug discovery, and potential commercialization of treatments for various cancers, including kidney, lung, gastrointestinal, and pancreatic cancers.

Arcus Biosciences is headquartered in Hayward, California, United States. The company primarily serves the US market, as indicated by its description focusing on developing and commercializing therapies in the United States. Its clinical trials and collaborations, such as those with AstraZeneca and Bristol-Myers Squibb, are likely conducted globally, but its core operations and target market are US-based.

Arcus Biosciences is a clinical-stage biopharmaceutical company, meaning it has not yet generated revenue from product sales. Its business model involves advancing a pipeline of cancer therapies through clinical trials, with the goal of obtaining regulatory approval and eventually commercializing them. The company generates revenue primarily through collaborations and partnerships, such as its agreements with AstraZeneca and Bristol-Myers Squibb, which may include upfront payments, milestone payments, and royalties. Additionally, it has a partnership with BVF Partners for inflammatory disease compounds. Until its drugs are approved, Arcus relies on funding from investors, partnerships, and possibly debt or equity offerings to support its operations.